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Abstract
Drugs that are clinically effective against anxiety disorders modulate the innate defensive behaviour of rodents,
suggesting these illnesses reflect altered functioning in brain systems that process threat. This hypothesis is supported
in humans by the discovery that the intensity of threat-avoidance behaviour is altered by the benzodiazepine
anxiolytic lorazepam. However, these studies used healthy human participants, raising questions as to their validity in
anxiety disorder patients, as well as their generalisability beyond GABAergic benzodiazepine drugs. BNC210 is a novel
negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor and we recently used functional Magnetic
Resonance Imaging to show it reduced amygdala responses to fearful faces in generalised anxiety disorder patients.
Here we report the effect of BNC210 on the intensity of threat-avoidance behaviour in 21 female GAD patients from
the same cohort. We used the Joystick Operated Runway Task as our behavioural measure, which is a computerised
human translation of the Mouse Defense Test Battery, and the Spielberger state anxiety inventory as our measure of
state affect. Using a repeated-measures, within-subjects design we assessed the effect of BNC210 at two dose levels
versus placebo (300 mg and 2000 mg) upon two types of threat-avoidance behaviour (Flight Intensity and Risk
Assessment Intensity). We also tested the effects of 1.5 mg of the benzodiazepine lorazepam as an active control.
BNC210 significantly reduced Flight Intensity relative to placebo and the low dose of BNC210 also significantly
reduced self-reported state anxiety. Risk Assessment Intensity was not significantly affected. Results show both human
defensive behaviour and state anxiety are influenced by cholinergic neurotransmission and there provide converging
evidence that this system has potential as a novel target for anxiolytic pharmacotherapy.
Introduction
Generalised Anxiety Disorder (GAD) is characterised by
chronically elevated levels of anxiety and affects millions of
people worldwide1. Benzodiazepines are effective for acute
anxiety treatment but have debilitating side effects, such as
addiction and sedation2. Selective serotonin reuptake
inhibitor antidepressants (SSRIs) are also used for anxiety
treatment but suffer from slow onset of action and side
effects including weight gain, sexual dysfunction, and
sleepiness3. This situation has prompted a search for new
molecules that can match or exceed the therapeutic effects
of existing anxiolytics yet possess novel mechanisms of
action that provide rapid relief without side effects.
One candidate molecule is the negative allosteric
modulator (NAM) of the alpha 7 nicotinic acetylcholine
receptor (α7 nAChR). This molecule is known as BNC210
and pre-clinical work has shown it is safe, well-tolerated
and non-sedating4. We recently found evidence from
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functional Magnetic Resonance Imaging (fMRI) that
BNC210 engages threat-processing brain systems, as it
significantly reduced amygdala reactivity to fearful faces
compared to placebo in a cohort of 24 GAD patients, as
well as reducing connectivity between the amygdala and
the anterior cingulate cortex5.
Here we sought behavioural evidence by measuring the
effect of BNC210 on the intensity of threat-avoidance
behaviour in 21 female GAD patients from the same cohort
as in our fMRI study. We measured participants’ defensive
behaviour using an ethoexperimental paradigm known as
the Joystick Operated Runway Task (JORT)6,7. The JORT is
a computerised human translation of the Mouse Defense
Test Battery (MDTB; Fig. 1a)8, which is an ethoexperi-
mental task that has been used to show that the innate
defensive behaviour of rodents is sensitive to drugs with
clinical effectiveness against anxiety disorders9–11. These
rodent experiments show drugs such as SSRIs, which are
clinically effective against panic disorder (PD), alter beha-
viour elicited by clear threat, such as running or jumping
away from threat (usually labelled as flight behaviour). In
contrast, drugs that are clinically effective against GAD,
such as benzodiazepines, alter goal-conflict-related beha-
viour elicited by potential threat, such as environmental
scanning and forward-backwards oscillation (usually label-
led as risk assessment behaviour)12.
In lieu of a physical runway, the JORT combines a force-
sensing joystick with an on-screen runway to measure the
intensity of simple avoidance behaviour (labelled Flight
Intensity; Fig. 1c, d) and two-way active avoidance behaviour
(labelled Risk Assessment Intensity; Fig. 1e, f). JORT studies
in healthy humans indicate human defensive behaviour is
sensitive to anti-anxiety medication but have not shown the
pharmacological distinction between flight and risk assess-
ment seen in rodents. For example, in a repeated-measures,
placebo-controlled study of 30 healthy human adult males,
acute doses of 10mg of the SSRI citalopram did not sig-
nificantly affect Flight Intensity. However, 1mg lorazepam
significantly reduced Risk Assessment Intensity6. In 40
healthy adults (20 males, 20 females), contrary to predictions,
there was no significant effect of 1mg or 2mg lorazepam on
Risk Assessment Intensity but a significant dose-dependent
effect of lorazepam on Flight Intensity in interaction with
personality. Lorazepam reduced Flight Intensity in high
scorers on the Tissue Damage Subscale of the Fear Survey
Schedule but increased it in low scorers7. More recently, in a
healthy German cohort studied after data collection ceased
for the present experiment, 0.5mg and 1mg lorazepam did
not affect Flight Intensity, whereas 0.5mg lorazepam sig-
nificantly reduced Risk Assessment Intensity relative to pla-
cebo but 1mg lorazepam failed to do so13. These findings
suggest the relationship between human defensive behaviour
Fig. 1 The ethoexperimental approach to measuring the intensity of threat-avoidance behaviour. a The Mouse Defense Test Battery. b The
Joystick Operated Runway Task. A force-sensing interface controls the speed of a green dot cursor pursued along a runway by a red dot cursor
capable of inflicting electric shock. The task comprised 12 trials each of pursuit (c), pursuit plus threat of electric shock (d), goal conflict (e), goal
conflict plus threat of electric shock (f). Illustration by Nick Boon.
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and anxiety is complex and requires further investigation. As
an exploratory test of BNC210 effects on threat-avoidance
behaviour, we conducted a placebo-controlled, repeated
measures experiment to test the effects of two doses of
BNC210 (300mg/2000mg) and 1.5mg lorazepam (as an
active control) on the JORT variables Flight Intensity and
Risk Assessment Intensity.
Methods
Participants were recruited according to the flow chart
shown in Fig. 2. Advertisements for the study contained a
weblink for a 50-item online Big Five personality ques-
tionnaire (the Trait Self-Description Inventory; TSDI)
that generated a detailed personality profile for each
respondent14. A total of 6293 people completed the
questionnaire, 862 of whom met the key requirement of
scoring one standard deviation or more above the mean
on neuroticism as well as other study requirements (e.g.,
local to the study site and a non-smoker). These indivi-
duals automatically received a message accompanying
their personality profile that contained information about
the study and invited them to contact the research team if
Fig. 2 Flow chart showing the exclusion path and numbers. Abbreviations: TSDI, Trait Self-Description Inventory; MINI, Mini International
Neuropsychiatric Interview; GAD, generalised anxiety disorder; MADRS, Montgomery-Asberg Depression Rating Scale; MRI, magnetic resonance imaging.
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interested in participating. Of those 862 eligible indivi-
duals, 226 contacted the team and 173 were telephone
screened, with 53 attending the study site for medical
checks. The on-site checks excluded 25 of the 53 potential
participants for reasons that could not be assessed during
telephone screening, such as abnormal blood test results.
Five candidates were excluded as they did not meet the
DSM-IV criteria for GAD, which was an inclusion
requirement of the study and was measured by the Mini
International Neuropsychiatric Interview (MINI)15. To
minimise co-morbidity with depression, seven partici-
pants who scored higher than 15 on the Montgomery-
Asberg Depression Rating Scale (MADRS)16 were also
excluded, as were those with any other significant psy-
chiatric or physical illness.
This process resulted in the enrolment of twenty-eight
individuals, 24 of whom completed the trial, including 21
females who are the subjects of this study (mean age 22.24
years; SD 3.52 years; age range 19–33 years). All partici-
pants provided informed consent, and the study was
approved by the NRES ethics committee Chelsea, London
(14/LO/2127).
This study was a repeated-measures, double-blind,
randomised, placebo-controlled trial. Each participant
attended four testing sessions and received either
2000 mg BNC210, 300 mg BNC210, 1.5 mg lorazepam or
placebo in each visit, in a randomised order. Sessions
were spaced a minimum of five days apart, to allow for
pharmacological wash-out. BNC210 was orally adminis-
tered as liquid suspension, with lorazepam orally admi-
nistered in encapsulated tablet form. The placebo was
presented either as a liquid or a capsule, depending upon
which drug it was replacing. Prior to each dosing session
participants had a medical health check and a standar-
dised high fat breakfast. Tmax of BNC210 and lorazepam
are approximately five hours and two hours, respectively.
To maintain the blind, the dosing schedule therefore
contained two dose administrations per session, with the
liquid dose administered five hours before testing and the
capsule dose two hours before testing. One of these doses
was always placebo except in the placebo condition when
both were placebo. This arrangement allowed each drug
to reach Tmax around the time when the testing
session began.
At enrolment, participants completed the Hamilton
Anxiety Rating Scale (HAM-A)17. Self-report state anxiety
was assessed by the state subscale of the Spielberger State-
Trait Anxiety Inventory (STAI)18 at three timepoints;
prior to first drug administration, immediately prior to
JORT testing, and immediately prior to discharge at the
end of the testing session (approximately seven hours
after dosing). This questionnaire is a widely used self-
report measure of subjective anxiety in clinical practice
and has been found to be a reliable tool19. It comprises
two scales of 20 items asking participants to report their
feelings of anxiousness: the STAI State scale evaluated
feelings at the time of completing the questionnaire and
the STAI Trait scale evaluated how the subject generally
felt. The former was administered at the three listed time
points, the latter only during screening. Responses were
marked on a 4-point scale from “not at all” to “very much
so.” We also administered the Fear Survey Schedule
(FSS)20 and as in previous experiments individual differ-
ences in fear-proneness modulated drug effects on
defensive behaviour7.
JORT testing was accomplished in the supine position
during fMRI scanning (Fig. 1) with a view to studying
drug effects on brain activity during threat-avoidance
behaviour. It should be noted however, that inability of
participants to keep their heads sufficiently still in the
MRI scanner while operating the joystick prevented col-
lection of useable fMRI data.
The JORT is a computerised human translation of the
MDTB8 (Fig. 1a) where a green dot cursor represents the
participant in an on-screen runway and threat stimuli are
represented by red dots. The participant used a force-
sensing joystick (PH-JS14-MRI; Psyal, London, UK) to
accelerate the green dot along the runway: the more force
applied to the joystick, the faster the green dot cursor
moved (Fig. 1b). In 50% of trials, a lightning flash icon was
displayed, signifying that if the green dot was caught by a
red dot, the participant would receive an electric shock.
The fMRI version of the JORT delivered electric shocks to
the right foot using a custom-built fMRI compatible
electrical stimulator. Each participant chose a shock level
they found annoying but not painful, from a choice of
eight levels (maximum 80 volts at 20 mA).
The JORT measures the intensity of two types of threat-
avoidance behaviour, Flight Intensity which is theoreti-
cally associated with fear and Risk Assessment Intensity
which is theoretically associated with anxiety. Flight
Intensity is calculated as average velocity in the one-way
active avoidance trials that contained no threat of electric
shock (Fig. 1c) subtracted from the average velocity in the
one-way active avoidance trials with a threat of electric
shock (Fig. 1d). Risk Assessment Intensity is calculated as
the standard deviation of the average velocity in the two-
way active avoidance trials that contained no threat of
electric shock (Fig. 1e) subtracted from the standard
deviation of the average velocity in the two-way active
avoidance trials with threat of electric shock (Fig. 1f). The
two-way active avoidance trials differ from the simple
avoidance trials in that they contain a second red dot
ahead of the green dot cursor, placing the participant in a
goal conflict situation in which they must move fast
enough to avoid the pursuing red dot but not so fast that
they collide with the red dot in front. This difference in
score methodology allows the JORT to control for any
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extraneous factors such as sedative effects of the drugs
which may be present in threat and non-threat trials.
There were 12 trials for each of the four task conditions,
giving a total of 48 trials. Each pursuit lasted for a max-
imum of seven seconds and terminated early in the event
of collision between the green and the red dot. An early
collision during pursuit did not reduce the total duration
of the trial, hence participants could not shorten the
testing session by failing to respond. To enhance unpre-
dictability, trials were presented in pseudo-random order
and intertrial intervals were varied pseudo-randomly
(between 15 and 30 s). The testing procedure was done
in the same order for all participants.
Statistical analysis
In order to test for dose-response effects of BNC210 upon
Flight Intensity and Risk Assessment Intensity, we conducted
repeated measures ANOVAs with a three-level within-sub-
jects factor that comprised zero dose BNC210 (placebo), low
dose BNC210 (300mg) and high dose BNC210 (2000mg).
We used previous JORT data to estimate a significant effect
could be detected with approximately 20 participants. The
final cohort totalled 24 participants but only female data (21
participants) were used to clarify the analysis, as there are
significant sex differences in susceptibility to anxiety dis-
orders21,22. Simple contrasts were used to test for the specific
direction of drug effects against placebo. To benchmark
BNC210 against the industry standard for anxiolytic drugs,
the ANOVAs were then repeated with lorazepam added as
an active control with simple contrasts again used to test for
the specific direction of drug effects against placebo. Repe-
ated measures ANOVAs with a three-level within-subjects
time factor were also used to test drug effects on STAI state




Table 1 shows the means, SDs and intercorrelations for
the HAM-A, STAI, neuroticism and FSS scores for the
study cohort. The average HAM-A score placed partici-
pants in the mild-moderate range of clinical anxiety.
HAM-A scores correlated significantly positively with
MADRS scores, as well as FSS social fear and STAI trait
anxiety but not FSS tissue damage fear. STAI state
anxiety scores at the three time points (pre-dose, pre-
JORT and pre-discharge) correlated significantly posi-
tively with trait anxiety scores (9 out of 12 correlations)
and with each other (64 out of 66 correlations). There
were no significant drug effects on STAI state anxiety
scores across the three specified time points for three out
of four conditions (placebo, lorazepam, high dose of
BNC210): placebo F (2, 19) = 2.64, P= 0.084, ƞp2=
0.122; lorazepam F (2, 19) = 1.53, P= 0.229, ƞp2= 0.071;
high BNC210 F (2, 19) = 2.671, P= 0.082, ƞp2= 0.118.
The low dose of BNC210 was the only condition to show
a significant main effect of drug on STAI state anxiety: F
(2, 19) = 7.53, P= 0.002, ƞp2= 0.273. Simple contrasts
showed that the low dose of BNC210 caused a significant
reduction in state anxiety between the pre-dose admin-
istration of the STAI and the STAI administered before
the JORT testing session: F (1, 20) = 11.53, P= 0.003,
ƞp2= 0.366. This effect became non-significant by the
time the participant was discharged from the test site. F
(1, 20) = 0.24, P= 0.630, ƞp2= 0.012. (Fig. 3).
Behavioural results
ANOVA results show a significant main effect of drug
on Flight Intensity: F (2, 19) = 4.03, P= 0.026, ƞp2=
0.168. Simple contrasts showed that both low and high
doses of BNC210 significantly reduced Flight Intensity
relative to placebo, but that the low dose exerted a greater
effect: F (1, 20) = 8.90, P= 0.007, ƞp2= 0.308; F (1, 20) =
5.22, P= 0.033, ƞp2= 0.207. There was no significant
main effect of drug on Risk Assessment Intensity: F (2, 19)
= 1.45, P= 0.247, ƞp2= 0.067. The addition of lorazepam
to the ANOVA reduced the main effect of drug on Flight
Intensity to statistical insignificance: F (3, 18) = 1.98, P=
0.126, ƞp2= 0.090. Simple contrasts showed that the
effect of lorazepam on Flight Intensity failed to reach
statistical significance: F (1, 20) = 2.07, P= 0.165, ƞp2=
0.094 (Fig. 4). The addition of lorazepam to the ANOVA
also showed no significant main effect of drug on Risk
Assessment Intensity: F (3, 18)= 1.11, P= 0.351, ƞp2=
0.053. Simple contrasts showed the effect of lorazepam on
Risk Assessment Intensity failed to reach statistical sig-
nificance: F (1, 20)= 1.43, P= 0.245, ƞp2= 0.067 (Fig. 5).
Discussion
We investigated the effect of a novel α7 nAChR NAM,
BNC210, on the intensity of threat-avoidance behaviour
in 21 adult female GAD sufferers using JORT.
BNC210 significantly reduced Flight Intensity relative to
placebo and more effectively than lorazepam. Neither
drug significantly altered Risk Assessment Intensity rela-
tive to placebo. The low dose of BNC210 also significantly
reduced self-reported state anxiety. The capacity of
BNC210 to reduce both the intensity of threat-avoidance
behaviour and self-reported state anxiety therefore pro-
vides converging evidence that it has promise as an
anxiolytic drug.
In line with previous experiments that tested the effects
of anxiolytics on human defensive behaviour6,7,13, our
BNC210 results suggest it too affects brain systems that
control defensive behaviour. But as in previous research,
the detailed pattern of results is not as clear as rodent
findings, which show a distinct behavioural/pharmacolo-
gical division between panic and anxiety, with the former









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Perkins et al. Translational Psychiatry           (2021) 11:13 Page 6 of 10
emotion being linked to flight behaviour and the latter to
risk assessment12. This inter-species difference may reflect
the greater cortical elaboration of humans providing a
greater role for abstract thought in response to threat, due
to what has been dubbed the “experiment-knowledge
problem”23. For example, the informed consent process
means that, unlike rodents, humans know that by volun-
teering for a JORT experiment, they will be exposed to
noxious stimuli. The knowledge of the unpleasant physical
events that will happen in the JORT testing room means
Fig. 3 Drug effects on Spielberger State Anxiety. State anxiety was significantly decreased by the low dose of BNC210 (n= 21, error bars= 1 SEM).
Fig. 4 Drug effects on Flight Intensity as measured by the Joystick Operated Runway Task (JORT). Flight Intensity was significantly decreased
by both low and high doses of BNC210 but not by lorazepam (n= 21, error bars= 1 SEM).
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that entering it is itself an anxiety-eliciting approach-to-
threat situation for humans. Under such circumstances it
is plausible that anxiolytics may affect human behaviour in
JORT trial types that contain no explicit goal conflict, such
as the simple avoidance trials used to measure Flight
Intensity, whereas the drugs do not show such effects in
rodents.
Our data also require some qualifications to be con-
sidered. Most importantly, results show both low and high
doses of the candidate anxiolytic drug BNC210 significantly
reduced Flight Intensity relative to placebo, but as a u-
shaped relationship in which the low dose of BNC210 was
most effective. This latter result echoes the findings of our
recent fMRI study in this same cohort, suggesting that
although it could perhaps be a cohort effect, it is not a
methodological artefact, as the fMRI data showed the low
dose of BNC210 was the most potent in reducing amygdala
reactivity to fearful faces compared to placebo and also
reduced connectivity between the amygdala and the ante-
rior cingulate cortex5. In that paper we suggested that the
effects of BNC210 may be explained by suppressive action
on glutamatergic interneurons in the basolateral amygdala.
Since we here obtained a similar pattern of results with the
behavioural data, it seems likely that a similar explanation is
also plausible. For example, if it is true that in GAD suf-
ferers, the excitatory/inhibitory balance has been lost and
the system contains too much glutamate and not enough
GABA, then it may be the case that the 300mg dose of
BNC210 is sufficient to restore homoeostasis by decreasing
glutamate release in the amygdala and hippocampus but the
2000mg dose of BNC210 destabilises the system, returning
it to the excessive glutamate situation.
A u-shaped dose response pattern is termed hormesis24,25
and is thought to occur when the balance of a homoeostatic
system is optimised by a low dose of a drug but destabilised
by either a high dose or no dose/placebo26. The amygdala is
one of the brain regions highly regulated by cholinergic input
and it has been shown in mice that activation of presynaptic
nAChRs can modulate both glutamatergic (excitatory) and
GABAergic (inhibitory) synaptic transmission. This mod-
ulation is sensitive to α-bungarotoxin, an α7 nAChR-specific
antagonist thus suggesting a role for α7 receptors26. Other
experiments in rats have shown that α7 nAChRs are the
predominant nicotinic receptor subtype expressed on the
somato-dendritic regions of a subset of amygdala neurons in
the basolateral amygdala and lateral nuclei27. Neuroscientific
work suggests these neurons form part of a group of brain
regions that have been dubbed the “cognitive fear” circuitry,
which controls appraisal of threat28.
Together these fMRI and behavioural data gathered in
this GAD cohort suggest that α7 nAChRs are important for
regulating excitability in regions of the amygdala that are
related to perceptions of threat intensity. In the case of
BNC210 in our anxious subjects, it may be that the 300mg
dose was optimal for balancing glutamatergic (excitatory)
and GABAergic (inhibitory) synaptic transmission in
response to threat, whereas the placebo and 2000mg con-
ditions were not.
Fig. 5 Drug effects on Risk Assessment Intensity as measured by the Joystick Operated Runway Task (JORT). Risk Assessment Intensity was
not significantly altered by BNC210 or lorazepam (n= 21, error bars= 1 SEM).
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Hence, viewed as a whole, the results of our two
BNC210 studies, which used different methods (fMRI and
JORT respectively) in the same cohort of GAD subjects,
support the notion that anxiety disorders reflect altered
functioning in brain systems that process threat9–12. They
also suggest that the novel α7 nAChR negative allosteric
modulator BNC210 at the 300mg dose has potential as an
anti-anxiety medication, perhaps because it restores the
homoeostatic balance between glutamatergic and GABAer-
gic systems.
This conclusion must be tempered with the finding that
neither BNC210 nor lorazepam had a significant effect on
Risk Assessment Intensity. This may have been a product
of suboptimal dose selection, as German work published
after these data were collected showed 0.5 mg lorazepam
reduced Risk Assessment Intensity13. Given that in rodent
work risk assessment behaviour is only seen at inter-
mediate threat levels, anxiolytic drugs can increase or
decrease values depending on the threat level. It is pos-
sible therefore that Risk Assessment Intensity is sensitive
to lower doses of drugs than Flight Intensity and with
hindsight we should have used a lower dose range for
lorazepam in the present study.
Conclusions must also be tempered by the finding that
self-reported state anxiety as measured by the Spielberger
STAI was not affected by lorazepam or the high dose of
BNC210. However, as shown in Fig. 3, the low dose of
BNC210 did significantly reduce state anxiety before the
JORT testing session, a finding that echoes its reducing
effect on Flight Intensity. Since Spielberger state anxiety is
a self-report method and the JORT is a behavioural
method, the cross-methodological convergence of
BNC210 effects suggests these findings are not artefactual
quirks of a particular method but may be due to a genuine
anxiolytic effect of BNC210, at least in the 300mg dose.
As a caveat it should be noted that our participants were
all female due to difficulties in recruiting sufficient male
GAD sufferers to obtain a balanced sample. With regard
to the female findings, sex differences in the neurobiology
of fear have been identified, which have substantial
implications for anxiety disorders29. Women are twice as
likely to have an anxiety disorder21,22. Emerging evidence
suggests that men and women differ in how they form
conditional fear memories and extinguish fear mem-
ories30, hence the discovery that BNC210 reduced threat-
avoidance intensity in our female participants is reassur-
ing evidence as to the clinical utility of BNC210. Previous
research into lorazepam effects on the threat-avoidance
behaviour of healthy participants contained equal num-
bers of both sexes and did not show this sex specific
effect7 suggesting that had we managed to recruit equal
numbers of males and females the BNC210 effect may
have been present in both. This situation makes a larger
scale replication of the present experiment with equal
numbers of males and females a matter of considerable
scientific importance.
As mentioned above, previous published work by our
team, using this same cohort, showed that the low dose of
BNC210 reduces amygdala responses to fearful faces and
reduces task-related anterior-cingulate functional con-
nectivity in a sample of individuals with GAD5. Our
behavioural and self-reported state anxiety data comple-
ment that work since amygdala hyperactivity to threat-
related stimuli reflects anxiety31,32, and marketed anxio-
lytic drugs altering the GABAergic and serotonergic sys-
tems, reduce amygdala responses to these stimuli33,34.
Viewed together, these findings suggest normalisation of
amygdala response may underpin the clinical effects of
anxiolytic medications which reduce anxiety and threat
avoidance behaviour. Our research in this GAD cohort
therefore provided several useful pieces of information. It
established that regions of the brain that are involved in
anxiety can be positively affected by BNC210, and it
showed that the drug could then induce defence-related
behaviour changes as demonstrated by the JORT. These
results respectively provide a physiological and a func-
tional basis to support the potential anxiolytic activity of
modulators of cholinergic transmission such as BNC210.
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